Examining how recent trial data are informing patient selection, treatment pathways, and multidisciplinary care.
MENLO PARK, Calif., Feb. 20, 2024 /PRNewswire/ -- Endovascular Engineering, Inc. ("E2"), a pioneering medical device company at the forefront of advancing clot removal technologies for venous ...
MENLO PARK, Calif., May 6, 2024 /PRNewswire/ -- Endovascular Engineering, Inc. ("E2"), a pioneering medical device company at the forefront of advancing clot removal technologies for venous ...
MENLO PARK, Calif., June 23, 2025 /PRNewswire/ -- E2 (Endovascular Engineering, Inc.), a medical device company advancing endovascular therapies, today announced the completion of patient enrollment ...
A small-profile thrombectomy device for the treatment of pulmonary embolism (PE) that suctions out and macerates the clot, allowing the blood to return to the patient at the procedure’s end, has met ...
MENLO PARK, Calif., April 7, 2026 /PRNewswire/ -- Endovascular Engineering, Inc. ("E2"), a commercial-stage medical technology company focused on advancing the treatment of venous thromboembolism (VTE ...
WASHINGTON, DC — Large-bore mechanical thrombectomy is superior to catheter-directed thrombolysis for pulmonary embolism, according to a randomized trial comparing the two interventions. Although ...
SAN FRANCISCO, CA—Patients with acute intermediate-high-risk pulmonary embolism (PE) who undergo mechanical thrombectomy have a greater reduction in the RV/LV ratio at 48 hours than those treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results